/
ARTL
$1.10-$0.02 (-1.79%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.9M
3M shares
52-week range
$1.03 – $85.80
0% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
26.58%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-309.40
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $1.2M | $1.1M | $1.9M | $2.8M | $4.3M | $5.7M | $6.0M | $5.4M |
| Operating income | −$2.3M | −$3.2M | −$4.7M | −$7.4M | −$10.3M | −$9.9M | −$10.1M | −$11.4M |
| EBITDA | −$2.3M | −$4.2M | −$4.7M | −$7.4M | −$10.1M | −$9.3M | −$9.8M | −$12.5M |
| Net income | −$2.3M | −$2.2M | −$4.7M | −$7.4M | −$10.1M | −$9.3M | −$9.8M | −$12.9M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -9.17 | -5.00 | -6.28 | -1.99 | -1.16 | -1.05 | -1.02 | -5.47 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-9.84 | $-9.84–$-9.84 | 1 |
| 2027 | $49M | $-5.28 | $-5.28–$-5.28 | 1 |
| 2028 | $100M | $12.60 | $12.60–$12.60 | 1 |
| 2029 | $185M | $30.15 | $30.15–$30.15 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Artelo Biosciences, Inc. Common Stock
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
www.artelobio.com- Employees
- 7
- IPO / List date
- Oct 13, 2015
- HQ
- SOLANA BEACH, CA
Held by traders on TradeandTell
No one on the platform currently holds ARTL.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ARTL as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-03-10 | 1-for-3reverse |
| 2025-06-13 | 1-for-6reverse |
| 2022-08-10 | 1-for-15reverse |
| 2019-06-21 | 1-for-8reverse |
Recent trades on TradeandTell
No one on the platform has traded ARTL yet.
